Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by Claridgeon May 31, 2019 2:24pm
118 Views
Post# 29789491

RE:Laser Division Tidbit from News

RE:Laser Division Tidbit from NewsEoganacht ... The re-design of the TLC-2000 will integrate the ability to reverse the Warburg effect, opening up the oncology market to pre-treat cancer patients in order to weaken their cancer cells prior to standard treatment of care (chemo, radiation, PDT/PDC, etc ...). 

Amazing breakthrough for the QOL of patients and increase the chances of oncology therapy success.

The re-design of the TLC-2000 was touted before these news releases.



November 27, 2017
 

Theralase Technologies has announced that its Theralase® therapeutic laser technology platform has been proven preclinically to render cancer cells more susceptible to cancer destruction by Photo Dynamic Therapy (“PDT”), by reversing the Warburg Effect.

One of the hallmarks of cancer cells is a change in cellular metabolism from mitochondrial respiration (the production of Adenosine TriPhosphate (“ATP”)) that relies on oxygen consumption to glycolysis, an oxygen independent process.

Cancer cells systematically modify their metabolism to promote their: growth, survival, proliferation and long-term maintenance, without the need for molecular oxygen, thus making them difficult to destroy by traditional means.

This common feature, amongst cancer cells, of a modified metabolism, is demonstrated by an increase in glucose (blood sugar) uptake and an increase in lactate production. This phenomenon was originally described by Dr. Otto Warburg at the turn of the 19th century, where he was awarded the Nobel prize in physiology or medicine for his work, and has subsequently been suitably named as the “Warburg Effect.”

The Warburg Effect describes cancer cells that are characterized by their decreased mitochondrial respiration, increased glycolysis (production of ATP without the use of molecular oxygen) and excessive lactate production.

Theralase’s TLC-2000 Cold Laser Therapy (“CLT”) was used to irradiate both in vitro GlioBlastoma Multiforme (“GBM”) Rat Glioma (“RG2”) brain and also transitional cell carcinoma bladder cancer cells (T24). The data below is for GBM RG2 cancer cells, but the CLT treatment of human bladder cancer cells rendered similar results on the Warburg Effect (data not shown)

Post treatment analysis of both of these cancer cell lines demonstrated a 20% decrease in the glycolysis rate (measured by a decrease in lactate production) and a 20% increase in mitochondrial respiration, leading to a shift in their metabolism (from cancerous to normal), indicating a reversal of the aptly named, Warburg Effect.
...

Accordingly, we strongly believe that technologies, like Theralase CLT, which have been proven preclinically to reverse the Warburg Effect, should be prioritized by researchers for the discovery of next generation anti-cancer therapeutic strategies. In our preclinical research, we used Theralase CLT as a modulator of cellular metabolism and were able to identify specific parameters that reverse the Warburg Effect, in laboratory cancer models. The results of our preclinical research demonstrate a significant unrealized potential of CLT, a therapeutic modality with over 50 years of clinical history that has been well recognized by Health Canada and the FDA as a safe and effective treatment of patients with chronic pain, now being able to provide an elegant way to fight cancer. Theralase, by building on the technology that commenced their early success in pain management, has now demonstrated the ability to employ this technology as a disruptive innovation in the destruction of cancer.”
 

 
November 30, 2017
 

Cancer cells modify their cellular metabolism to ensure their survival and proliferation, thus making them difficult to destroy by standard cancer treatments.

Theralase has demonstrated, in previous research, preclinically, that its Theralase® CLT, using specific laser energy dosages, is able to reverse the Warburg Effect in cancer cells making them more susceptible to destruction from other forms of therapy.

Building upon these findings, Theralase has discovered that its Theralase® CLT, due to its ability to stimulate cancer cells to reverse the Warburg Effect, has now been demonstrated effective, preclinically, to enhance cancer destruction by several standard cancer treatments; including: ionizing radiation (X-rays) and chemotherapy (anti-cancer drugs Cisplatin and Temozolomide (“TMZ”)), as well as Photo Dynamic Therapy (“PDT”), increasing the efficacy of these treatments, while potentially decreasing their associated toxic side effects.

Theralase® CLT is cleared by Health Canada and the Food and Drug Administration for the treatment of chronic knee pain and in off label use, the treatment of numerous nerve, muscle and joint conditions by: reducing/eliminating pain, reducing inflammation and accelerating healing.

...
 

Arkady Mandel, MD, Ph.D., D.Sc., Chief Scientific Officer, Theralase stated that, “One of the key strategies of our scientific team’s Theralase® CLT preclinical development program is to break down preconceived notions pertaining to CLT with new scientific, preclinical and clinical knowledge of how Theralase® CLT works so effectively on tissues: including, discoveries of previously unknown therapeutic pathways, such as mitochondria independent cellular signalling mechanisms. This enables our scientific team to build strategies to re-shape the use of Theralase® CLT from its existing therapeutic market and launch it into the oncology market, as a stand-alone therapy or to be used in conjunction with other anti-cancer treatments. A significant number of in vitro and animal cancer models have been evaluated with Theralase® CLT, such as: cisplatin, temozolomide, PDT and X-rays, building a body of evidence that significant and transferable anti-tumour effects of Theralase® CLT is applicable across a number of diverse tumour cell lines. The preclinical data of our research demonstrates the Theralase® CLT potential for the treatment of different type of cancers. The development of the Theralase® CLT technology may introduce new applications of this technology allowing new patient populations to benefit from Theralase® CLT treatment.

Roger Dumoulin-White, P.Eng., President and CEO, Theralase stated, “The latest research from Dr. Mandel and his scientific team opens up new potential distribution possibilities for both the Therapeutic Laser Therapy (“TLT”) division and the Photo Dynamic Therapy (“PDT”) division. Theralase will focus on translating this preclinical research into clinical protocols that could be readily deployed in the clinic by healthcare practitioners to pre-treat patients suffering with various cancer conditions with a goal of increasing the efficacy of their present anti-cancer treatments, lowering any associated side effects and increasing their overall QOL.”

_________________

Eoganacht - (5/31/2019 1:56:06 PM) 

Laser Division Tidbit from News

"As of March  25, 2019,  the Company has  recommenced development of  the next generation TLC2000  laser system with an expected completion in 2H2019."

Bullboard Posts